1.FGFR1 selective inhibitor PD173074 can reduce proliferation and induce apoptosis of nasopharyngeal carcinoma.
Hong LUAN ; Yunfei XU ; Tingting FU ; Yan LUAN ; Cunli YUAN
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2014;28(20):1579-1584
OBJECTIVE:
To study the influence of PD173074 on proliferation and apoptosis of nasopharyngeal carcinoma.
METHOD:
With immunoblotting and RT-PCR, FGFR1 expression was detected in CNE, PONE1 and C666-1 cell lines. With MTT assay,the time-effect and dose-effect correlation between PD173074 and inhibition of CNE proliferation was evaluated. After PD173074 stimulation, the phosphorylation level of FGFR1 and AKT was detected with immunoblotting assay. Furthermore, influence of PD173074 on the activation of Caspase3 and Caspase9 was detected to study the underlying mechanism of why PD173074 could inhibit CNE proliferation.
RESULT:
FGFR1 has the highest expression in CNE cell line. Under incubation of 10 nmol/L PD173074 stimulation for 36 hours to 72 hours, the phosphorylation of FGFR1 and AKT was impaired significantly, which further reduced the proliferation of CNE. Moreover, PD173074 can activate the intrinsic apoptotic pathway by stimulating Caspase9,which activated Caspase3 and induced the apoptosis.
CONCLUSION
PD173074 could inhibit proliferation of nasopharyngeal carcinoma cell through reducing the phosphorylation of FGFR1 and AKT. Additionally, PD173074 can induce CNE apoptosis by activating intrinsic apoptotic pathway via cleaving Caspase9 and Caspase3.
Antineoplastic Agents
;
pharmacology
;
Apoptosis
;
drug effects
;
Carcinoma
;
Caspase 3
;
metabolism
;
Cell Line, Tumor
;
Cell Proliferation
;
Humans
;
Nasopharyngeal Carcinoma
;
Nasopharyngeal Neoplasms
;
drug therapy
;
pathology
;
Pyrimidines
;
pharmacology